Moneycontrol PRO
Upcoming Webinar:Watch a panel of experts discuss: Challenges of continuously evolving regulation for Cryptocurrency, on 7th July at 3pm. Register Now

Buy Aurobindo Pharma; target of Rs 985: Motilal Oswal

Motilal Oswal is bullish on Aurobindo Pharma recommended buy rating on the stock with a target price of Rs 985 in its research report dated October 26, 2020.

October 28, 2020 / 01:19 PM IST
  • bselive
  • nselive
Todays L/H

Motilal Oswal 's research report on Aurobindo Pharma

Aurobindo Pharma (ARBP) has announced the divestment of Natrol, a wholly-owned unit of its US-based subsidiary, for USD550m (~INR40b) as an all-cash deal. Considering Natrol's FY20 sales/PAT at USD157m/USD27m, the deal is attractive at valuation of 3.5x EV/Sales and 20x P/E on FY20 basis. -ARPB is expected to use the funds to further reduce its debt and strengthen future product pipeline. We have reduced our FY22E EPS estimate by 2.5% to INR62.2 to factor in the Natrol divestment and revised our price target to INR985 (from INR1,015 earlier), based on 16x 12M forward earnings. Re-iterate Buy.


We value ARBP at 16x 12M forward earnings to arrive at a target price of INR985. Re-iterate Buy.

For all recommendations report, click here


Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Oct 28, 2020 01:19 pm
ISO 27001 - BSI Assurance Mark